Prescribing Omnipod® 5

Simplify Life™ for adults living with type 1 diabetes (T1D)

Offer your patients the freedom and flexibility of on-body, personalised T1D control that improves glycaemic outcomes vs prior therapy, while improving patient-reported outcomes.*1,2

* Results from a pivotal single-arm, multicentre, prospective study in 112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years.1

With Omnipod® 5, you can offer your adult patients:

Omnipod - virtual customer service icon

Individualised delivery

Adjusting over time to your patients’ needs, with SmartAdjust™ technology to help protect them against highs and lows*†1

Pod | Simplify life Omnipod®

Everyday freedom

Tubeless, waterproof, on-body, Automated Insulin Delivery (AID), so there is no need to disconnect from AID for showering or exercise.

Pod | Simplify life Omnipod®

Improved outcomes vs prior therapy

Improved glycaemic outcomes that go hand-in-hand with improved patient-reported outcomes, such as reduced diabetes distress and lower stress when eating†1,2

* If glucose alerts and readings from Dexcom G6 do not match your patient’s symptoms or expectations, a blood glucose meter should be used to make diabetes treatment decisions.
† Results from a pivotal single-arm, multicentre, prospective study in 112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years.1
‡ The Pod has a waterproof IP28 rating for up to 7.62 m (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.

See the clinical evidence for yourself

The benefits of Omnipod® 5 in adults and adolescents with T1D have been established in a pivotal, prospective clinical trial. Significant improvements were demonstrated in glycaemic control with Omnipod® 5 vs prior therapy, alongside improvements in psychosocial outcomes.*1-3

* Results from a pivotal single-arm, multicentre, prospective study in 112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years.1

Which of your adult patients may benefit from Omnipod® 5?

Active lifestyle and lives alone
Miles, 64

  • Machinist, nearing retirement
  • Active lifestyle, on the job and through daily exercise
  • Widowed; lives alone
  • Diagnosed with T1D over 40 years ago
  • HbA1c over 9% and total daily dose is 65 units
  • Despite his best efforts, his HbA1c is not at goal and he is worried about hypoglycaemia, particularly overnight
  • He uses a glucose sensor currently, but fears wearing a pump and the complexity it would bring

Omnipod® 5 may help to simplify Miles’ management of his T1D, if he can be offered reassurance to address his concerns. Switching to Omnipod® 5 has demonstrated improved glycaemic control vs prior therapy, an important potential benefit for Miles, who is not reaching glycaemic goals.1

On AID but not usually in automated mode
Janet, 34

  • Middle school teacher
  • Busy mother of 3 young girls
  • Diagnosed with T1D 15 years ago
  • HbA1c over 7%, and tends to experience hyperglycaemia throughout the day
  • Currently using an AID pump and is not tempted to switch
  • Not spending the majority of time in automated mode

Omnipod® 5 can offer Janet the benefits of simplified T1D management. She already utilises AID, however she does not spend most of her time in automated mode. Omnipod® 5 can offer improvements in glycaemic control vs prior therapy, and 96.7% of adults stayed in automated mode in a pivotal study.1 This is an important potential benefit for Janet, whose glucose levels tend to run high throughout the day.

Life with the Pod: Meet some of our Podders® and hear their stories

 
 
 

Arrange a meeting with an Omnipod® representative

Do you have questions about Omnipod®? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod®.

Prescribing for Children

Find out how Omnipod® 5 can improve outcomes vs prior therapy for children with T1D.3

Be the first to know

Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.

References: 1. Brown S et al. Diabetes Care 2021 ;44 :1630-1640. 2. Polonsky WH et al. Diabetes Technol Ther 2016;18(10):664-670. 3. Sherr J et al. Diabetes Care 2022;45:1907-1910.